Trial Profile
XELJANZ (REGISTERED) TABLETS 5MG SPECIAL INVESTIGATION (ALL-CASES SURVEILLANCE)
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 29 Sep 2021
Price :
$35
*
At a glance
- Drugs Tofacitinib (Primary) ; Disease-modifying antirheumatics; Etanercept
- Indications Rheumatoid arthritis
- Focus Adverse reactions; Therapeutic Use
- Sponsors Pfizer
- 27 Sep 2021 Status changed from active, no longer recruiting to completed.
- 27 Oct 2020 Planned End Date changed from 15 Dec 2020 to 16 Mar 2021.
- 27 Oct 2020 Planned primary completion date changed from 15 Dec 2020 to 16 Mar 2021.